Antiplatelet agents and arterial thrombosis

Area of Science:

• Geriatric Medicine
• Cardiovascular Medicine
• Pharmacology

Background:

• Arterial thrombotic events disproportionately increase in the elderly.
• Older patients often have comorbidities (diabetes, hypertension, hypercholesterolemia) that exacerbate risk.
• Antithrombotic therapy is underutilized in geriatric populations, even when safe.

Purpose of the Study:

• To review the efficacy and safety of antiplatelet agents in the elderly.
• To assess the impact of antiplatelet therapy in various disease states within this demographic.
• To highlight the underuse of antithrombotic treatments in geriatric patients.

Main Methods:

• Review of available antiplatelet agents: aspirin, clopidogrel, and glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists.
• Analysis of clinical data focusing on the geriatric population.
• Assessment of drug effects across different disease states relevant to the elderly.

Main Results:

• Elderly patients exhibit a disproportionately higher risk of arterial ischemic events.
• Comorbidities like diabetes, hypertension, and hypercholesterolemia significantly increase this risk.
• Current antithrombotic therapy use in the elderly is suboptimal, irrespective of contraindications.

Conclusions:

• Antiplatelet agents (aspirin, clopidogrel, GPIIb/IIIa antagonists) have a crucial role in managing thrombotic risk in the elderly.
• Further research and clinical attention are needed to address the underutilization of these therapies in geriatric patients.
• Optimizing antithrombotic strategies is essential for reducing arterial thrombotic events in the aging population.